User menu

Renal Tissue-injury and Proliferative Response After Successive Treatments With Anticancer Platinum Derivatives and Tobramycin

Bibliographic reference Nonclercq, D. ; Toubeau, G. ; Tulkens, Paul M. ; Heusonstiennon, JA. ; Laurent, G.. Renal Tissue-injury and Proliferative Response After Successive Treatments With Anticancer Platinum Derivatives and Tobramycin. In: Virchows Archiv. Section B: Cell Pathology, Vol. 59, no. 3, p. 143-158 (1990)
Permanent URL
  1. Bennett WM (1989) Mechanisms of aminoglycoside nephrotoxicity. Clin Exp Pharmacol Physiol 16:1–6
  2. Bregman CL, Williams PD (1986) Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer Chemother Pharmacol 18:117–123
  3. Burton K., A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid, 10.1042/bj0620315
  4. Calvert AH, Harland SJ, Newell RD, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147
  5. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KW (1985) Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev [Suppl A] 12:51–57
  6. Calvert AH (1986) Clinical application of platinum metal complexes. In: McBrien DCH, Slater TF (eds) Biochemical mechanisms of platinum antitumor drugs. I.R.L. Press Lim Oxford, pp 307–328
  7. Carlier MB (1984) La phospholipidose rénale induite par les aminoglycosides. Etude biochimique et morphologique. Thesis Université Catholique de Louvain, Belgium
  8. Choie DD, Langnecker DS, del Campo AA (1981) Acute and chronic cis-platin nephropathy in rat. Lab Invest 44:397–402
  9. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF (1982) Cis-diamminedichloroplatinum-induced acute renal failure in the rat. Kidney Int 21:54–64
  10. Cuppage FE, Tate A (1967) Repair of the nephron following injury with mercuric chloride. Am J Pathol 51:405–429
  11. Cuppage FE, Cunningham N, Tate A (1969) Nucleic acid synthesis in the regenerating nephron following injury with mercuric chloride. Lab Invest 21:449–457
  12. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551–556
  13. Dobyan DC, Hill D, Lewis T, Bulger RE (1981) Cyst formation in rat kidney induced by cis-platinum administration. Lab Invest 45:260–268
  14. Dobyan DC (1985) Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec 212:239–245
  15. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA (1988) Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited smallcell lung cancer. J Clin Oncol 6:451–456
  16. Engineer MS, Bodey GP, Newman RA, Ho DW (1987) Effects of cisplatin-induced nephrotoxicity on gentamicin pharmacokinetics in rats. J Pharmacol Exp Ther 15:329–334
  17. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, De Gregorio M (1989) Evaluation of cisplatin dose intensity: current status and future prospects. Anticanc Res 9:1121–1128
  18. Ghadially FN (1982) Ultrastructural pathology of the cell and matrix. Butterworths, London, p 558
  19. Giuliano RA, Verpooten GA, Verbist L, Wedeen R, De Broe ME (1986) In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 236:470–475
  20. Haas A., Anderson L., Lad T., The Influence of Aminoglycosides on the Nephrotoxicity of cis-Diamminedichloroplatinum in Cancer Patients, 10.1093/infdis/147.2.363
  21. Holleran WM, De Gregorio MW (1988) Evolution of high-dose cisplatin. Invest New Drugs 6:135–142
  22. Houghton DC, Lee E, Gilbert DN, Bennett WM (1986) Chronic gentamicin nephrotoxicity: continued tubular injury with preserved glomerular filtration function. Am J Pathol 123:183–194
  23. Jones TW, Chopra S, Kaufman JS, Flamenbaum W, Trump BF (1985) Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Lab Invest 52:363–374
  24. Kahlmeter G., Dahlager J. I., Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982, 10.1093/jac/13.suppl_a.9
  25. Kawamura J, Soeda A, Yoshida O (1981) Nephrotoxicity of cisdiamminedichloroplatinum (II) (cis-Platinum) and the additive effect of antibiotics: morphological and functional observation in rats. Toxicol Appl Pharmacol 58:475–482
  26. Kosek J, Mazze R, Cousins M (1974) Nephrotoxicity of gentamicin. Lab Invest 30:48–57
  27. Laurent G, Maldague P, Carlier M B, Tulkens P M, Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats., 10.1128/aac.24.4.586
  28. Laurent G, Toubeau G, Heuson-Stiennon JA, Tulkens PM, Maldague P (1988a) Kidney tissue repair after nephrotoxic injury: Biochemical and morphological characterization. CRC Crit Rev Toxicol 19:147–183
  29. Laurent G, Yernaux V, Nonclercq D, Toubeau G, Maldague P, Tulkens PM, Heuson-Stiennon JA (1988b) Tissue injury and proliferative response induced in rat kidney by cis-diammine dichloroplatinum II. Virchows Arch [B] 55:129–145
  30. Lietman PS (1985) Aminoglycosides and spectinomycin: Aminocyclitols. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases. Wiley, New York, pp 192–206
  31. LOEHRER PATRICK J., Cisplatin, 10.7326/0003-4819-100-5-704
  32. Luft F. C., Kleit S. A., Renal Parenchymal Accumulation of Aminoglycoside Antibiotics in Rats, 10.1093/infdis/130.6.656
  33. Mavichak V, Wong NLN, Quamme GA, Sutton RAL, Dirks JH (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in the rat. Kidney Int 28:914–921
  34. Meijer D, Sleijfer DT, Mulder NH, Donker AJM (1982) Cisplatininduced nephrotoxicity. Neth J Med 25:262–269
  35. Munro HN, Fleck A (1966) The determination of nucleic acids. Meth Biochem Anal 14:113–176
  36. Nichols CR, Loehrer PJ, Greist A, Kubilis PS, Hoffman R (1988) Salvage chemotherapy for lymphoma with VP-16, ifofamide, and cisplatin. Med Pediatr Oncol 16:12–16
  37. Nonclercq D, Toubeau G, Laurent G, Maldague P, Tulkens P, Heuson-Stiennon JA (1988) Light and electron microscopic characterization of the proliferative response induced by tobramycin in rat kidney cortex. Exp Mol Pathol 48:335–352
  38. Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA (1989a) Nephrotoxic injury and renal tissue repair associated with the administration of the anticancer drugs cisplatin and carboplatin. Micron Microscop Acta 20:51–58
  39. Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA (1989b) Tissue injury and repair in the rat kidney after exposure to cisplatin and carboplatin. Exp Mol Pathol 51:123–140
  40. Peckham M J, Horwich A, Hendry W F, Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8), 10.1038/bjc.1985.141
  41. Prestayko AW (1981) Cisplatin and analogues: a new class of anticancer drugs. In: Crooke ST, Prestayko AW (eds) Cancer and chemotherapy, vol III, antineoplatic agents. Academic Press, New York, pp 133–154
  42. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH (1988) Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol 6:1239–1247
  43. Safirstein R, Winston J, Guttenplan G (1986) Cisplatin nephrotoxicity: physiological and biochemical aspects. In: McBrien, Slater TF (eds) Biochemical mechanisms of platinum antitumor drugs. I.R.L. Press Lim, Oxford, pp 271–306
  44. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity: insight into mechanism. Int J Androl 10:325–346
  45. Safirstein R., Zelent A. Z., Gordon R., Cisplatin Nephrotoxicity: New Insights Into Mechanism, Organ Directed Toxicities of Anticancer Drugs (1988) ISBN:9781461292050 p.172-189, 10.1007/978-1-4613-2023-4_17
  46. Sande MA, Mandell GL (1985) Antimicrobial agents. The aminoglycosides. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 1150–1169
  47. Schroyens WA, Meeker JB, Dodion P, Stryckmans PA, Rozencweig M (1988) Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay. Eur J Cancer Clin Oncol 24:1309–1312
  48. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, Yarnold J, Glees JP, Baker J, Ford HT (1985) Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69:43–46
  49. Tay LK, Bregman CL, Masters BA, Williams PD (1988) Effects of cis-diamminedichloroplatinum (II) on rabbit kidney in vivo and on rabbit renal proximal tubule cells in culture. Cancer Res 48:2538–2543
  50. Ten Bokkel Huinink WW, Van Der Burg MEL, Van Oosterom AT, Neijt JP, George M, Guastala JP, Veenhof CHN, Rotmensz N, Dalesio O, Vermorken JB (1988) Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev [Suppl B] 15:9–15
  51. Toubeau G, Laurent G, Carlier MB, Abid S, Maldague P, Heuson-Stiennon JA, Tulkens P (1986a) Tissue repair in rat kidney cortex after short treatment with aminoglycosides at low doses. A comparative biochemical and morphometric study. Lab Invest 54:385–393
  52. Toubeau G, Maldague P, Laurent G, Vaamonde CA, Tulkens PM, Heuson-Stiennon JA (1986b) Morphological alterations in distal and collecting tubules of the rat renal cortex after aminoglycoside administration at low doses. Virchows Arch [B] 51:475–485
  53. Tulkens PM (1989) Nephrotoxicty of aminoglycoside antibiotics. Toxicol Lett 46:107–123
  54. Ward JM, Fauvie KA (1976) The nephrotoxic effects of cis-diamminedi-chloroplatinum II (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535–547
  55. Watanabe M (1978) Drug-induced lysosomal changes and nephrotoxicity in rats. Acta Pathol Jpn 28:867–889
  56. Wiltshaw E, Evans BD, Jones AC, Baker JW, Calvert AH (1983) JM8 successor to cisplatin in advanced ovarian carcinoma? Lancet 1:587
  57. Wiltshaw E, Evans B, Harland S (1985) Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV. Proc Am Assoc Clin Oncol 4: 121